Nextage Therapeutics Ltd Cash Flow-to-Debt Ratio
Nextage Therapeutics Ltd cash flow-to-debt ratio. Nextage Therapeutics Ltd (NXTG) has a Cash Flow-to-Debt Ratio of -0.97x as of June 2022, meaning its operating cash flow of ILA-1.72 Million could theoretically repay -1% of its total liabilities (ILA1.77 Million) in one year. See Nextage Therapeutics Ltd leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Nextage Therapeutics Ltd (2017–2024)
Cash flow-to-debt ratio of Nextage Therapeutics Ltd from 2017 to 2024. Historical debt coverage capacity for Nextage Therapeutics Ltd across 8 annual periods. Also explore NXTG net asset momentum to track the company's year-over-year net asset growth rate.
Nextage Therapeutics Ltd Cash Flow-to-Debt Ratio by Year (2017–2024)
Nextage Therapeutics Ltd cash flow-to-debt ratio by year from 2017 to 2024. Year-by-year debt coverage analysis for Nextage Therapeutics Ltd. For the full cash flow conversion analysis, see Nextage Therapeutics Ltd operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (ILA) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.13x | ILA-795.00K | ILA5.89 Million | ▲ +77.1% |
| 2023 | -0.59x | ILA-2.26 Million | ILA3.83 Million | ▲ +81.0% |
| 2022 | -3.10x | ILA-6.01 Million | ILA1.94 Million | ▼ -193.2% |
| 2021 | -1.06x | ILA-3.97 Million | ILA3.76 Million | ▲ +56.1% |
| 2020 | -2.41x | ILA-6.31 Million | ILA2.62 Million | ▼ -93.1% |
| 2019 | -1.25x | ILA-2.93 Million | ILA2.35 Million | ▼ -79.5% |
| 2018 | -0.70x | ILA-4.95 Million | ILA7.12 Million | ▲ +2.5% |
| 2017 | -0.71x | ILA-5.67 Million | ILA7.96 Million | — |